Synthekine il-12
WebMay 26, 2024 · He has been responsible for resolving the structure-function relationship of more than a dozen cytokines, starting with IL-2 back in the 2000s to, most recently, IL-12, … WebFunding Round • Jan 6, 2024. Synthekine raised $100,000,000 / Series C from The Column Group. Discover more funding rounds. News • Jan 6, 2024. BioSpace — Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics. News Jan 6, 2024. VC News Daily — Synthekine Secures $100M Series C Financing.
Synthekine il-12
Did you know?
WebInterleukin-12 (IL-12) is a heterodimeric cytokine produced mostly by phagocytic cells in response to bacteria, bacterial products, and intracellular parasites, and to some degree by B lymphocytes. IL-12 induces cytokine production, primarily of IFN-gamma, from NK and T cells, acts as a growth facto … WebNov 14, 2024 · The deal comes just a few days after Synthekine secured approval to start clinical trials in the US of its lead drug candidate STK-012, a partial agonist of the cytokine IL-2 ... Wednesday 12 ...
WebJan 6, 2024 · Preclinical data for Synthekine’s IL-12 partial agonist program demonstrates potent anti-tumor efficacy in mouse models while avoiding induction of systemic toxicity. WebApr 9, 2024 · PARIS – April 9, 2024 – Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April 10 as a late-breaking poster presentation …
WebMar 1, 2024 · Thus, a variety of engineering and drug delivery approaches to improve the antitumor and pharmacological properties of interferons are under investigation, particularly for IFNα. In this section we review the three major interferon classes and recent advances in the use of interferons for the treatment of cancer. 3.4.1. WebMar 1, 1994 · NK cells are a subpopulation of lymphocytes that kill virally infected cells and tumor cells without previous sensitization. Although exposure to distinct cytokines, including IL-2 and IL-12, can enhance these cytotoxic responses, the mechanism of this lymphokine-augmented killing remains unclear. I …
Web2 days ago · Systemically administered wild-type IL-12 has been shown to cause significant toxicity. Our approach with STK-026 leverages Synthekine’s expertise in structural biology, immunology, and protein engineering to bias IL-12 activity and expand the therapeutic index.” Details are as follows and available on the AACR online itinerary planner:
WebDec 22, 2024 · An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. ... Synthekine, Menlo Park, CA 94025, USA. ORCIDs linked to this article. Riener R ... Front Immunol, 12:745320, 12 Oct 2024 Cited by: 2 articles PMID: 34712233 PMCID: ... how to view gopro videos on laptopWebTo address the therapeutic index challenges of IL-2, we have designed our IL-2 partial agonist, STK-012, to bias its activity towards tumor antigen-activated T cells. We are also … how to view gpa in studentvueWeb2 days ago · Systemically administered wild-type IL-12 has been shown to cause significant toxicity. Our approach with STK-026 leverages Synthekine’s expertise in structural biology, immunology, and protein engineering to bias IL-12 activity and expand the therapeutic index.” Details are as follows and available on the AACR online itinerary planner: how to view gopro videos on windows 10WebFeb 18, 2024 · Synthekine. IL-2 partial agonist, targeting activated T cells. IND in 2024. KY1043. Kymab. IL-2v–anti-PDL1 mAb fusion protein. IND in 2024. BNT151. BioNTech. IL-2v, mRNA encoded. IND in 2024 ... orif with percutaneous pinning cptWebSynthekine 该公司专注于开发第一代和第二代干细胞来源的NK细胞，作为治疗癌症的基本手段。 此次即将公布数据的候选产品STK-026设计了一种新型人IL-12部分激动剂，被用于更具选择性地参与抗原激活的T细胞并减少对NK细胞的刺激。 orif with fnsWeb2 days ago · Systemically administered wild-type IL-12 has been shown to cause significant toxicity. Our approach with STK-026 leverages Synthekine’s expertise in structural biology, immunology, and protein engineering to bias IL-12 activity and expand the therapeutic index.” Details are as follows and available on the AACR online itinerary planner: orif with lcpWebDec 27, 2024 · SYNCAR-001 + STK-009 is a 2-component human orthogonal (ho) IL-2 receptor-ligand cell therapy consisting of (1) SYNCAR-001, a CD19-directed chimeric antigen receptor T cell ... Synthekine: ClinicalTrials.gov Identifier: NCT05665062 Other Study ID Numbers: STK-009-101 : First Posted: orif with intramedullary nailing